Sterling Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$50.9K Buy
2,024
+1,822
+902% +$49.6K ﹤0.01% 1757
2026
Q2
$5.45K Sell
202
-104
-34% -$2.85K ﹤0.01% 2562
2026
Q1
$8.29K Hold
306
– – ﹤0.01% 2481
2025
Q4
$11.1K Buy
306
+211
+222% +$8.46K ﹤0.01% 2552
2025
Q3
$3.6K Hold
95
– – ﹤0.01% 2866
2025
Q2
$1.28K Sell
95
-297
-76% -$4.3K ﹤0.01% 3018
2025
Q1
$6.22K Sell
392
-331
-46% -$3.81K ﹤0.01% 2048
2024
Q4
$8.9K Buy
723
+646
+839% +$8.45K ﹤0.01% 2212
2024
Q3
$932 Buy
+77
New +$932 ﹤0.01% 2568

Other funds holding MLYS

Sterling Capital Management's MLYS Position: Q3 2026 in Review

Sterling Capital Management increased its Mineralys Therapeutics (MLYS) stake by 902% in Q3 2026, buying an estimated $49.6K and bringing the position to 2,024 shares worth $50.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1757.

Sterling Capital Management first reported a position in MLYS in Q3 2024 and has held it in 9 quarters since. 219 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.

  • Sterling Capital Management held 2,024 shares of Mineralys Therapeutics worth $50.9K as of Q3 2026.
  • Sterling Capital Management bought 1,822 Mineralys Therapeutics shares in Q3 2026, an estimated $49.6K.
  • Mineralys Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #1757 holding.
  • Sterling Capital Management first reported a position in Mineralys Therapeutics in Q3 2024 and has held it in 9 quarters since.
  • 219 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.